MedTrace Logo

Docetaxel and Irinotecan in Gastric Cancer

NCT04770623 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-01-30

No results posted yet for this study

Summary

To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.

Conditions

Interventions

DRUG

Docetaxel

patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival

DRUG

Irinotecan

patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2023-01-09
Completion
2023-01-09

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770623 on ClinicalTrials.gov